JPWO2021208963A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021208963A5 JPWO2021208963A5 JP2022554627A JP2022554627A JPWO2021208963A5 JP WO2021208963 A5 JPWO2021208963 A5 JP WO2021208963A5 JP 2022554627 A JP2022554627 A JP 2022554627A JP 2022554627 A JP2022554627 A JP 2022554627A JP WO2021208963 A5 JPWO2021208963 A5 JP WO2021208963A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- cycloalkyl
- optionally substituted
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 —C 3-8 cycloalkyl Chemical group 0.000 claims 82
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 125000000623 heterocyclic group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 11
- 229910052757 nitrogen Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 239000001301 oxygen Substances 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000011593 sulfur Chemical group 0.000 claims 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000003566 oxetanyl group Chemical group 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 claims 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims 1
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000003331 prothrombotic effect Effects 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/084992 | 2020-04-15 | ||
| CN2020084992 | 2020-04-15 | ||
| CN2020100472 | 2020-07-06 | ||
| CNPCT/CN2020/100472 | 2020-07-06 | ||
| CN2020125580 | 2020-10-30 | ||
| CNPCT/CN2020/125580 | 2020-10-30 | ||
| CNPCT/CN2021/075831 | 2021-02-07 | ||
| CN2021075831 | 2021-02-07 | ||
| CN2021086189 | 2021-04-09 | ||
| CNPCT/CN2021/086189 | 2021-04-09 | ||
| PCT/CN2021/087225 WO2021208963A1 (en) | 2020-04-15 | 2021-04-14 | Bcl-2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520843A JP2023520843A (ja) | 2023-05-22 |
| JPWO2021208963A5 true JPWO2021208963A5 (de) | 2024-04-16 |
Family
ID=78083530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554627A Pending JP2023520843A (ja) | 2020-04-15 | 2021-04-14 | Ｂｃｌ－２阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230159522A1 (de) |
| EP (1) | EP4136084A4 (de) |
| JP (1) | JP2023520843A (de) |
| KR (1) | KR20230002419A (de) |
| CN (3) | CN116802179A (de) |
| AU (1) | AU2021256580A1 (de) |
| BR (1) | BR112022019525A2 (de) |
| CA (1) | CA3172478A1 (de) |
| IL (1) | IL296582A (de) |
| MX (1) | MX2022013006A (de) |
| TW (1) | TW202200574A (de) |
| WO (1) | WO2021208963A1 (de) |
| ZA (1) | ZA202209891B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022213335A1 (en) * | 2021-04-09 | 2022-10-13 | Beigene (Beijing) Co., Ltd. | Method for preparing intermediate of bcl-2 inhibitor |
| WO2023078398A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| CA3238781A1 (en) * | 2021-11-20 | 2022-11-10 | Hongbin Liu | Compounds as bcl-2 inhibitors |
| AU2022406595A1 (en) * | 2021-12-06 | 2024-05-16 | Guangdong Hongye Pharmaceutical Co., Ltd. | Anti-apoptotic protein bcl-2 inhibitor, pharmaceutical composition and uses thereof |
| WO2023122000A1 (en) * | 2021-12-20 | 2023-06-29 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| CN114292192A (zh) * | 2022-01-17 | 2022-04-08 | 山东泓瑞医药科技股份公司 | 一种3,4-二甲氧基苯甲酸甲酯的合成方法 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023231777A1 (en) * | 2022-06-01 | 2023-12-07 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106749233B (zh) * | 2016-11-24 | 2020-04-21 | 中山大学 | 一类磺酰胺衍生物及其应用 |
| CN106809678B (zh) * | 2017-01-03 | 2018-02-23 | 东莞理工学院 | 一种新旧smt接料带的粘接机 |
| CA3098348A1 (en) * | 2018-04-29 | 2019-11-07 | Beigene, Ltd. | Bcl-2 inhibitors |
| WO2020140005A2 (en) * | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2022213335A1 (en) * | 2021-04-09 | 2022-10-13 | Beigene (Beijing) Co., Ltd. | Method for preparing intermediate of bcl-2 inhibitor |
-
2021
- 2021-04-14 TW TW110113455A patent/TW202200574A/zh unknown
- 2021-04-14 IL IL296582A patent/IL296582A/en unknown
- 2021-04-14 JP JP2022554627A patent/JP2023520843A/ja active Pending
- 2021-04-14 EP EP21789482.3A patent/EP4136084A4/de active Pending
- 2021-04-14 MX MX2022013006A patent/MX2022013006A/es unknown
- 2021-04-14 WO PCT/CN2021/087225 patent/WO2021208963A1/en active Application Filing
- 2021-04-14 CN CN202180029718.1A patent/CN116802179A/zh active Pending
- 2021-04-14 CN CN202310560508.6A patent/CN116969937A/zh active Pending
- 2021-04-14 KR KR1020227035815A patent/KR20230002419A/ko active Search and Examination
- 2021-04-14 BR BR112022019525A patent/BR112022019525A2/pt unknown
- 2021-04-14 CA CA3172478A patent/CA3172478A1/en active Pending
- 2021-04-14 CN CN202310559385.4A patent/CN116969936A/zh active Pending
- 2021-04-14 AU AU2021256580A patent/AU2021256580A1/en active Pending
- 2021-04-14 US US17/916,845 patent/US20230159522A1/en active Pending
-
2022
- 2022-09-05 ZA ZA2022/09891A patent/ZA202209891B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5746631B2 (ja) | ベンゾフラン誘導体 | |
| JP6211530B2 (ja) | 含窒素複素環化合物 | |
| HRP20180371T1 (hr) | Novi derivati piridina | |
| JP5937674B2 (ja) | 癌の治療用のｐｉ３−キナーゼ阻害剤としてのクロメノン化合物 | |
| JPWO2021208963A5 (de) | ||
| RU2016129018A (ru) | Производные оксиндола, их получение и терапевтическое применение при лечении заболеваний, связанных с амрк | |
| RU2015108894A (ru) | СОЕДИНЕНИЯ 4-ГЕТЕРОАРИЛЗАМЕЩЕННОЙ БЕНЗОЙНОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ | |
| RU2017116598A (ru) | Соединения и композиции для модуляции киназной активности мутантов egfr | |
| RU2011107437A (ru) | Ингибиторы кинуренин-3-моноксигеназы | |
| RU2017146661A (ru) | Замещенные пиридины и способ их применения | |
| JP3922884B2 (ja) | ベンゾフリルピロン誘導体 | |
| RU2014124950A (ru) | Производные 2-фениламинопиримидина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2) для лечения болезни паркинсона | |
| WO2013053051A1 (en) | Indazole compounds as kinase inhibitors and method of treating cancer with same | |
| JPWO2013161919A1 (ja) | Ｔｒｋ阻害化合物 | |
| JP2015526441A5 (de) | ||
| JP2011511001A5 (de) | ||
| JP2014520885A5 (de) | ||
| JP2017523223A5 (de) | ||
| JP2019537590A5 (de) | ||
| JP2008528663A (ja) | Ｔｉｅｓ（ＴＥＫ）阻害活性を有するピリミジン化合物 | |
| JP2016514709A (ja) | ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン | |
| RU2753524C2 (ru) | Бициклические азотсодержащие гетероциклические производные и включающие их фармацевтические композиции | |
| CN108069955B (zh) | 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用 | |
| JP2008534481A (ja) | インスリン様増殖因子−１受容体活性の阻害剤としての２−アゼチジニル−４−（１ｈ−ピラゾール−３−イルアミノ）ピリミジン | |
| JP2016515573A (ja) | Ｃｅｔｐ抑制活性を有する新規なオキサゾリジノン誘導体、その製造方法およびこれを含む薬学組成物 |